Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients.
Harding
G F
GF
D000927:Anticonvulsants / Q000009:adverse effects*; D006801:Humans; D018570:Risk Assessment; D020888:Vigabatrin; D014786:Vision Disorders / Q000139:chemically induced*; D014794:Visual Fields; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives*
D000927:Anticonvulsants; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin